Attendee search 

PressCise is a research project from CHalmers and University of Gothenburg aimed at developing a unique bandage. The bandage will be used for remediation including varicose vein surgery and should be easy to wrap.

Immunicum AB (publ) develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX®, in addition to the method for expansion of tumor-specific T-cells (CD70), are based on the Nobel Prize awarded discovery of dendritic cells (DCs) and their central role in all immune responses. Since the raw material consists of white blood cells (DCs) from healthy donors, Immunicum’s products can be mass-produced.

The therapeutic cancer vaccine INTUVAX® is injected intratumorally and is currently being evaluated in a clinical Phase I/II-study in metastatic renal cell carcinoma. It utilizes each patient’s own unique tumor tissue as antigen source and is thus a completely personalized therapeutic cancer vaccine that is still able to mass-produce and store in frozen condition for long periods of time.

• controlling stem cell differentiation into liver and heart cells which offer unrivalled performance in toxicity testing applications;
• ownership and exploitation of the world's largest stem cell bank (30 proprietary lines);
• effective industrial rollout of their technologies;
• alongside leading partners, involvement in regenerative medicine programs which use the immense potential of stem cells for the restoration of damaged tissues and organs.

• To industrialize pluripotent stem cells;
• To develop industrial in vitro tools predictive of human physiology and genetic diversity, such as tools for the drug and cosmetic industries, as well as for research, and that can be immediately used in industrial molecular screening and selection processes;
• To develop major partnerships, particularly in the field of regenerative medicine;
• To take a strategic industrial role in order to set standards in an emerging market, forge a strong pioneering position in the areas of focus, and build a genuine industrial sector based around stem cells and a competitive industrial cluster.

Red Glead Discovery has two main business areas: CRO services and internal early drug discovery projects. Our focus is on the development of drugs based on small molecules and peptides.

Our first-rate drug discovery services include integrated lead discovery, based on competence and long-standing experience. In-house laboratory capabilities comprise medicinal chemistry, assay development and screening, radioisotope-labelling, analytical chemistry, in vitro profiling and NMR.

An expert area is generation of chemical starting points for drug targets and to develop them into patentable lead compounds with drug-like properties and low risk profile. Our project management skills and cross-disciplinary capabilities make us a preferred partner for clients that want to develop compounds with high potential to become successful drugs.

Truly Translational Sweden AB offers consultancy combined with specialized experimental services within translational science.

Our mission is to help our customers to translate preclinical project ideas into efficient experimental plans delivering successful clinical trials.

Truly Translational is founded on solid scientific expertise and more than 50 years experience with drug research & development in both large pharma and biotech. We help our customers bringing drug projects from preclinical in vitro studies and animal models via common biomarker strategies, into concept testing in patients. Our experience covers both small molecules and biologicals, and we are familiar with the special requirements for different routes of administration, for example inhaled drugs.

iliod is a pharmaceutical development company aiming at developing a novel infective agent until phase II clinical trials. iliod is founded on the core assets of three patent applications, know-how and experience of the active protein, a network both within academia and industry and a dedicated team with a drive to make a difference for the future of healthcare.

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The Company's pipeline currently includes three product candidates for the treatment of cancer.

Our mission is to generate value for shareholders by building a sustainable portfolio of clinical development projects and, over time, successfully launching several innovative drugs.

In order to maximise the value of the Company we plan to:

• Commercialise product candidates in co-operation with partners.
• Retain rights to individual geographic markets for particular products where we consider that it would be feasible to establish a competitive sales and marketing force.
• Broaden and expand our product portfolio to create more opportunities for generating successful products and increasing the likelihood of commercial success for the Company as a whole.
• Gain access to innovative target proteins and/or projects from external research groups and use these as a basis for generating novel therapeutics using our proprietary technology platform.

Our revenues include licence fees, milestone payments, compensation of manufacturing and royalties on sales derived from our co-operation agreements around our product candidates. We also generate income by providing discovery development to our customers.

We expect to achieve sustainable profitability as soon as one of our products reaches the market. However, profits may be reported in certain years before this as projects reach key milestones that trigger payments from partners.

APL is a full scale Contract Development and Manufacturing Organisation. Modern manufacturing processes and staff with cutting edge competence make APL a competent partner and supplier. We develop and manufacture pharmaceuticals and consumables for companies throughout the world. Our offers extend from the early research phase to commercial product.